Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
55.32
+0.68 (1.24%)
Sep 1, 2026, 10:06 AM EDT - Market open
Exelixis Revenue
Exelixis had revenue of $628.69M in the quarter ending July 3, 2026, with 10.63% growth. This brings the company's revenue in the last twelve months to $2.44B, up 9.23% year-over-year. In the year 2025, Exelixis had annual revenue of $2.32B with 6.98% growth.
Revenue (ttm)
$2.44B
Revenue Growth
+9.23%
P/S Ratio
5.56
Revenue / Employee
$2,261,764
Employees
1,077
Market Cap
13.71B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.32B | 151.43M | 6.98% |
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
| Dec 31, 2018 | 853.83M | 401.35M | 88.70% |
| Dec 31, 2017 | 452.48M | 261.02M | 136.34% |
| Dec 31, 2016 | 191.45M | 154.28M | 415.05% |
| Dec 31, 2015 | 37.17M | 12.06M | 48.03% |
| Dec 31, 2014 | 25.11M | -6.23M | -19.87% |
| Dec 31, 2013 | 31.34M | -16.11M | -33.96% |
| Dec 31, 2012 | 47.45M | -242.19M | -83.62% |
| Dec 31, 2011 | 289.64M | 104.59M | 56.52% |
| Dec 31, 2010 | 185.05M | 33.29M | 21.93% |
| Dec 31, 2009 | 151.76M | 33.90M | 28.76% |
| Dec 31, 2008 | 117.86M | 4.39M | 3.87% |
| Dec 31, 2007 | 113.47M | 14.80M | 15.00% |
| Dec 31, 2006 | 98.67M | 22.71M | 29.90% |
| Dec 31, 2005 | 75.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.60B |
| BioMarin Pharmaceutical | 3.41B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 1.20B |
| Corcept Therapeutics | 830.81M |
| BridgeBio Pharma | 713.07M |
EXEL News
- 19 hours ago - Exelixis says appeals court affirmed ‘key portion’ of 2024 judgment - TheFly
- 19 hours ago - Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories - Business Wire
- 3 days ago - Strong Sales, Earnings Send Exelixis Shares Higher - FXEmpire
- 13 days ago - BMO starts Exelixis at Market Perform into patent cliff - TheFly
- 13 days ago - Exelixis initiated with a Market Perform at BMO Capital - TheFly
- 15 days ago - EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law - Business Wire
- 21 days ago - EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis - PRNewsWire
- 25 days ago - Leerink downgrades Exelixis to Market Perform following Q2 results - TheFly